All Articles

As students face a choice between their health and education, one foundation offers direct aid. But does this agile approach mask a deeper systemic failure?

With new HKEX rules mandating rigorous board reviews, companies are at a crossroads. Specialist firms like GreenCo offer a path beyond compliance.

RBC and BMO's $2 billion sale of Moneris isn't just a big payday. It's a strategic retreat from a complex market, fueling a new chapter for Canadian commerce.

A family-owned filter maker's acquisition of a century-old supplier isn't just a deal; it's a masterclass in operational expansion and customer retention.

Aardvark Therapeutics faces a pivotal moment as an FDA clinical hold halts its lead drug trial, leaving the Prader-Willi Syndrome community waiting.

Jatagan Security's new UL Solutions verification for its reporting process could finally bring clarity to an industry plagued by unsubstantiated claims.

CanNor's latest funding is not just about infrastructure; it's a strategic play on Indigenous-led economic sovereignty and the future of Canada's North.

Shareholders have approved Fairfax Financial's buyout of Andrew Peller Ltd., ending its public chapter. This isn't just a deal; it's a strategic uncorking.

Reed's Q2 results show major operational gains and a shrinking net loss, but a steep sales decline and a looming cash crunch raise critical questions.

With a NYSE delisting notice and a dividend under scrutiny, Lument Finance Trust's Q2 report is more than just numbers—it's a test of its strategy.

SINTX Technologies is shifting from R&D to sales, but its ambitious med-tech goals are balanced by a precarious financial reality. Is this a blueprint for resilience?

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?

NeuroPace reports strong Q2 growth and raises 2026 guidance, driven by its RNS system. A new AI tool and key clinical data signal a deeper push into personalized medicine.

Black Rock Coffee Bar reports a stellar quarter with 25% revenue growth, but a deeper look reveals the complex challenges of rapid expansion in a competitive market.

With FDA clearance for its AI burn scanner, Spectral AI faces its next test: conquering the market. Can it turn government contracts into commercial success?

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

AGT Food and Ingredients' Q2 results signal a successful shift to higher-margin foods, with its packaged foods segment surging despite global headwinds.

A sharp revenue drop and net loss for IZEA masks a major strategic pivot. With $46M in cash, the company is betting its future on enterprise clients.

A pivotal ATF ruling reclassifies the BolaWrap as a restraint tool, not a weapon. This opens a vast private market, but as the tool expands beyond police, new questions of oversight arise.

While the dry bulk market is strong, Pangaea's Q2 earnings reveal a model where specialized fleets and integrated logistics deliver superior, market-beating margins.